Wednesday, December 16, 2020
A subjective study has begun to assess the short- and long-term health outcomes of SARS-CoV-2 infection in children, including multisystem inflammatory syndrome in children (MIS-C), and to identify immunologic pathways associated with different disease manifestations and outcomes. SARS-CoV-2 is the virus that causes COVID-19. The study, called the Pediatric Research Immunization Network on SARS-CoV-2 and MIS-C (PRISM), will enroll at least 250 children and young adults aged 20 years and under from different racial and ethnic backgrounds at around 20 sites across the country. The study is funded and funded by the National Institute of Infectious Diseases and Infectious Diseases (NIAID), part of the National Institutes of Health. The PRISM study is part of a research effort led by the NIH National Institute of Heart, Lung and Blood and Eunice Kennedy Shriver National Institute for Child Health and Human Development to understand MIS-C.
Although SARS-CoV-2 infection usually causes either an illness or just a mild illness in children, some children become very ill at the time of the disease, and others do not have symptoms at first. developing MIS-C. MIS-C is a life-threatening condition characterized by severe inflammation in one or more parts of the body, including the heart, lungs, kidneys, brain, skin, eyes and gastrointestinal organs. . The syndrome usually begins several weeks after the onset of SARS-CoV-2 and disproportionately affects Black and Hispanic children.
“It is vital that we learn how to prevent and treat this rare but very severe syndrome in children,” said NIAID Director Anthony S. Fauci, MD “Information gathered during the study may help PRISM clinicians also ultimately detect and treat MIS-C to understand which children are susceptible to the disease. ”
PRISM study focuses on fillaps in understanding the clinical spectrum of COVID-19 in children and young adults, long-term results of SARS-CoV-2 infection in these populations, and the underlying immunologic basis of MIS-C. It is led by clinical protocol chair Steven A. Webber, MBCh.B., MRCP, chair of the children’s department at Monroe Carell Jr. Children’s Hospital. at Vanderbilt in Nashville, Tennessee.
The PRISM study team enrolled children and adult volunteers with visible SARS-CoV-2 in respiratory samples, with MIS-C markers, or both. Participants will be followed for at least a year.
The study has two main aims. The first is to determine the proportion of children who die, are re-hospitalized after first admission to hospital, or have serious health problems as a result. on SARS-CoV-2 at six and 12 months after initial presentation with COVID-19, MIS-C, or both. The second is to test the immunologic mechanisms and properties associated with different forms of MIS-C and COVID-19 in children. Results are expected in mid-2022.
More information about the PRISM study is available at ClinicalTrials.gov under study identifier NCT04588363.
NIAID conducts and supports research – at NIH, across the United States, and around the world – to investigate the causes of infectious and immunosuppressive diseases, and to develop better ways to prevent, diagnose and treat these diseases. Press releases, information sheets and other NIAID-related materials can be found on the NIAID website.
About the National Institutes of Health (NIH):
NIH, the nation’s medical research agency, comprises 27 Institutes and Centers and is part of the U.S. Department of Health and Human Services. NIH is the leading federal agency that conducts and supports basic, clinical and translational medical examination, and investigates causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH… Turning traces into health®